

**We claim:**

1. A pharmaceutical composition for oral administration comprising pilocarpine R-(+)-lipoate or its polymorphs, enantiomers, isomers; and its pharmaceutically acceptable salts thereof.
2. The pharmaceutical composition of claim 1, wherein the pilocarpine R-(+)-lipoate is formulated in an amount of 1% to 70% w/w of the composition; and (ii) one or more excipients in an amount of 30 – 99 % w/w of the composition.
3. The pharmaceutical composition of claim 2, wherein the pilocarpine-R-(+)-lipoate is in the range of 0.1 mg to 100 mg.
4. The pharmaceutical composition of claim 2, wherein the one or more excipients are selected from a diluent, a lubricant, a disintegrant, a polymer, a flavoring agent, a binder, a sweetening agent, a glidant, an antioxidant, coating material, or mixtures thereof.
5. The pharmaceutical composition of claim 4, wherein the diluent is selected from lactose, spray dried lactose, lactose monohydrate, lactose hydrous, lactose anhydrous, starches, maize starches, or partially pregelatinized starches, sucrose, magnesium stearate, glucose, micro crystalline cellulose, Polyvinylpyrrolidone, mannitol, sorbitol, dibasic calcium phosphate dehydrate, calcium sulphate dehydrate, calcium carbonate, or mixtures thereof.
6. The pharmaceutical composition of claim 4, wherein the disintegrant is selected from crosslinked polymer such as polyvinylpyrrolidone (crospovidone) or crosslinked sodium carboxymethylcellulose (croscarmellose sodium), microcrystalline cellulose (MCC), alginates or modified starches, such as sodium starch glycolate, or mixtures thereof.
7. The pharmaceutical composition of claim 4, wherein the polymer is selected from carbomers, polycarbophil, pemulen polymers, starch, modified cellulose, crystalline cellulose, microcrystalline cellulose, carboxymethyl cellulose, sodium carboxymethylcellulose, an acrylic acid copolymer, methyl vinyl ether copolymer with maleic anhydride, hydroxypropyl methylcellulose, polyglycolic acid, or mixtures thereof.
8. The pharmaceutical composition of claim 4, wherein the flavoring agent is selected from clove oil, citric syrup, glycerin, rose oil, orange oil, menthol, cherry, or mixtures thereof.
9. The pharmaceutical composition of claim 4, wherein the binder, is selected from saccharides and their derivatives such as starches, cornstarch, cellulose, methyl cellulose

and modified cellulose such as microcrystalline cellulose, cellulose ethers such as hydroxypropyl cellulose; sugar alcohols such as xylitol, sorbitol, or mannitol; protein: such as gelatin; synthetic polymers such as polyvinyl pyrrolidone (PVP), polyethylene glycol (PEG), or mixtures thereof.

10. The pharmaceutical composition of claim 4, wherein the sweetening agent is selected from sucrose, liquid glucose, glycerol, sorbitol, saccharin sodium, aspartame, or mixtures thereof.
11. The pharmaceutical composition of claim 4, wherein the glidant is selected from magnesium stearate, fumed silica (colloidal silicon dioxide), starch, talc, or mixtures thereof.
12. The pharmaceutical composition of claim 4, wherein the antioxidant is selected from butylated hydroxyanisole, butylated hydroxytoluene, sodium metabisulfite (SMB), propyl gallate (PG) cysteine (CYS), ascorbic acid, or mixtures thereof.
13. The pharmaceutical composition of claim 4, wherein the a coating material is selected from sugar, polymers, polysaccharides, moisture barrier coating material, cellulosic polymers, vinyl derivatives, hydroxypropyl cellulose, Hydroxyethyl cellulose microcrystalline cellulose, derivatives cellulose, alkylated cellulose, ethyl cellulose, propyl cellulose, hydroxylpropyl cellulose, sugar or a polysaccharide, hydroxypropyl methylcellulose, carboxymethylcellulose, maltodextrin, sucrose, modified starch, a salt of alginic acid, soluble gums, carrageenan, polymer comprises polyvinylpyrrolidone or polyvinylpolypyrrolidone, and Opadry film coating system.
14. The pharmaceutical composition of claim 4, wherein the coating of the composition is from sugar coatings, film coatings, gelatin coatings, enteric coatings, compression coatings, or immediate-release film coatings.
15. The pharmaceutical composition of claim 1, is a modified release composition wherein the modified release composition is formulated into mucoadhesive buccal tablet, lozenge, oral patch, oral film, buccal patch, oral spray, oral solution, oral gel, sub-lingual tablet, mucoadhesive patch or film or transdermal patch.

- 16.** The pharmaceutical composition of claim 15, wherein the modified release is controlled by polymers and pharmaceutically acceptable excipients to deliver extended release, sustained release, or delayed release.